Axsome Therapeutics, Inc. (AXSM), a commercial-stage biopharmaceutical company developing therapies for central nervous system (CNS) disorders, has seen its shares retreat sharply from their 52-week high. That pullback has widened the gap between the latest market price and the average analyst price target, raising a straightforward question for investors: can the stock climb back toward $275?
Axsome Therapeutics carries broad but not unanimous bullish coverage. Across the verified targets reviewed, the arithmetic mean comes to roughly $275, with the low-to-high span extending from approximately $238 to $380 — an unusually wide range that underscores how differently analysts model the company's path to profitability.
Recent revisions have skewed lower even as ratings remain positive. Mizuho trimmed its target to $284 (from $316), Piper Sandler to $238 (from $258), UBS to $256 (from $280), Deutsche Bank to $267 (from $280), and Morgan Stanley to $247, while RBC Capital, H.C. Wainwright, TD Cowen, and Truist maintained targets in the $285-to-$300 zone. These cuts followed a period of elevated expectations, reflecting more conservative near-term assumptions rather than a collapse in conviction — most firms still rate the shares Buy or Overweight.
The divergence is largely a question of valuation. Bullish analysts emphasize the growing Auvelity franchise and pipeline optionality, while more cautious voices, including Morgan Stanley's Equal Weight rating, argue that the current enterprise value already discounts meaningful execution and that profitability remains some distance away.
Axsome's stock closed near $144 in late October 2026, down roughly 31% over the prior three months and well below its 52-week range of approximately $123.50 to $260.19. Reaching the $275 central target would require a gain of about 90%, which must be characterized as a very large move rather than an incremental recovery.
The path would almost certainly be driven by fundamentals rather than sentiment alone. Axsome is not yet profitable on a GAAP basis, so the investment case rests on accelerating revenue and eventual operating leverage. In the third quarter, total revenue reached $259.7 million, up 52% year over year, led by Auvelity net product sales of $207.6 million (up 53%). Sunosi contributed $48.2 million and newly launched Symbravo $3.9 million. Management has pointed to a commercial portfolio running above a $1 billion annualized revenue pace.
From a technical standpoint, Axsome is trading in the lower portion of its long-term range. The 52-week low near $123.50 represents a key support level to watch, while the $200 area is a psychological and prior-consolidation resistance level on the way toward higher objectives. The stock's decline from roughly $260 to the $144 area leaves significant overhead supply, meaning any sustained advance toward $275 would likely need to be confirmed by improving fundamentals and a durable break back above the $200 zone.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. Investors should watch quarterly Auvelity and Sunosi trends, the Symbravo launch trajectory, regulatory decisions on AXS-12, and Phase 3 data readouts across the pipeline. Updates to analyst price targets, gross-to-net discount trends, and progress toward profitability will also be key signals for whether the gap to the $275 target narrows or widens.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like Axsome, where sentiment and catalysts can change quickly, this kind of automated monitoring can help traders discover opportunities, track positions, and spot changing trends more efficiently. Traders looking to complement fundamental research with data-driven timing may find the signal-based approach a useful addition to their workflow.
The $275 central target — the average of verified analyst price targets spanning roughly $238 to $380 — sits about 90% above Axsome's latest price, making it a demanding objective. Support comes from rapid Auvelity growth, a meaningful label expansion in Alzheimer's disease agitation, and a deep late-stage pipeline. The principal obstacles are ongoing losses, early-stage execution in newer products, clinical and regulatory uncertainty, and a recent pattern of downward target revisions. Whether the stock approaches $275 will depend heavily on continued commercial momentum and successful pipeline milestones, and investors should treat the wide analyst range as evidence that this outcome is far from assured.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with CYTK. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To AXSM | 1D Price Change % | ||
|---|---|---|---|---|
| AXSM | 100% | +5.23% | ||
| CYTK - AXSM | 42% Loosely correlated | +1.89% | ||
| PHVS - AXSM | 40% Loosely correlated | -1.39% | ||
| ARQT - AXSM | 38% Loosely correlated | +4.52% | ||
| RYTM - AXSM | 36% Loosely correlated | +0.01% | ||
| MIRM - AXSM | 36% Loosely correlated | +1.33% | ||
More | ||||